Since mutations in POLE confer increased disease free survival (DFS) in patients with uterine cancer, even in those patients with high-grade tumors [3, 42], we investigated the prognostic role of POLQ and REV3L mutations in POLE mutant tumors. Here, REV3L is linked to uterine cancer.